Emergent BioSolutions (EBS) Misses Q2 EPS by 43c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $8.28 --0%
Revenue Growth %: +32.0%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
CRMT, PKE, More
Revenue Growth %: +32.0%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($1.06), $0.43 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $337.9 million versus the consensus estimate of $217.03 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Solstice acquiring Element Solutions in $14.5B cash and stock deal
- Harley-Davidson (HOG) PT Raised to $30 at DA Davidson: 'Moving in The Right Direction'
- Solaris Energy acquires GESA for $55M cash and 3M shares
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
